Michael J. Abernathy, MS, RAC Amgen, Inc.

Michael Abernathy, Executive Director, leads Amgen’s Global RA CMC function and is accountable for more than 65 staff globally, and a product portfolio of over 80 programs. The extent of Michael’s product oversight and responsibilities traverse molecular discovery, early and late-stage clinical development and approved life-cycle programs. He also founded Amgen’s RA CMC External Engagement function targeting activities that comprise a CMC focus, promoting company and industry initiatives, engaging with Health Authorities around the world and contributing to industry organizations. Michael also is a member of Accumulus Synergy’s executive leadership team, and is the Product Owner for the development of company’s cloud-based Data Exchange application.

Prior to his current post, Michael has held roles of increasing leadership at Amgen, including active contributions to several of Amgen’s commercialized therapeutics, as well as spearheading the company’s Analytics Optimization initiative. Michael has been an active contributor to innovation during his 20+ years as a Regulatory Affairs professional. Prior to joining Amgen, he held a leadership role within Atrix Laboratories/QLT, Inc.’s Regulatory Affairs group. Mr. Abernathy holds degrees from University of the Pacific, California State University and Colorado State University.